Omnium News
DevelopingLive story

Do Ozempic and similar GLP-1 drugs increase the risk of a rare form of vision loss?

Current evidence suggests an association between GLP-1 receptor agonists and NAION, but it has not established that these drugs cause this rare form of vision loss.

Where the claims stand

4 corroborated1 supported

Reports linking Ozempic (semaglutide) and other GLP-1 receptor agonists to blindness have drawn widespread attention. The current evidence does not establish that these drugs cause blindness, but several observational studies have reported an association with non-arteritic anterior ischemic optic neuropathy (NAION), a rare form of sudden optic nerve injury. We are tracking whether accumulating evidence supports a causal relationship or whether the observed association is explained by underlying risk factors such as diabetes and vascular disease.

We’ll only notify you when something material changes.

Additional information

Status

as of July 1, 2026
Developing

Multiple independent observational studies have reported an association between GLP-1 receptor agonists and NAION, but none can establish causation. Researchers continue to investigate whether the relationship reflects a drug effect, characteristics of patients prescribed these medications, or other confounding factors. Regulators and ophthalmologists are monitoring the evidence, but no consensus has concluded that semaglutide causes NAION.

Confidence — current state

We are cautiously confident that there is a real signal worth investigating because multiple independent observational studies have reported elevated rates of NAION among GLP-1 receptor agonist users. However, the existing evidence remains observational and cannot determine causation.

This is our best read given the published evidence we have reviewed — not a claim of absolute truth.

Open questions

  • Does semaglutide itself increase the risk of NAION?

    Current studies are observational and cannot fully separate drug effects from patient risk factors.

  • Are some GLP-1 medications associated with higher risk than others?

    Different drugs may have different pharmacology or prescribing populations.

  • Which patients are most susceptible?

    Understanding individual risk could improve prescribing decisions without unnecessarily discouraging treatment.

  • What biological mechanism could explain the association?

    A plausible mechanism would strengthen evidence for causality.

What would change our mind

  • Large prospective studies finding no increased NAION risk after careful adjustment for diabetes severity and vascular risk factors.
  • Multiple independent studies consistently reproducing the association across different populations.
  • Mechanistic evidence demonstrating how GLP-1 receptor agonists could directly contribute to optic nerve injury.
  • Updated regulatory conclusions based on substantially larger bodies of evidence.

Claims & evidence

Each claim is tracked separately — not a single verdict.

  • Several observational studies have reported an association between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy (NAION).

    Corroborated
    Evidence basisPeer-reviewed · independently corroborated

  • Current evidence does not establish that Ozempic or semaglutide causes NAION.

    Supported
    Evidence basisPeer-reviewed · independently corroborated

  • NAION is a rare condition, even among patients taking GLP-1 receptor agonists.

    Corroborated
    Evidence basisPeer-reviewed · independently corroborated

  • People with diabetes already have a higher baseline risk of NAION than the general population.

    Corroborated
    Evidence basisOfficial statement · independently corroborated

  • The FDA-approved prescribing information for Ozempic does not currently identify NAION as an established adverse reaction.

    Corroborated
    Evidence basisOfficial statement · single source
    • Official statementJanuary 1, 2025
      Ozempic Prescribing Information

      “Current labeling does not list NAION as an established adverse reaction.”

How we got here

2 updates · append-only
  1. New evidence

    Professional societies urge caution in interpreting the findings

    Ophthalmology organizations noted that the observed association warrants further study but cautioned that patients should not interpret the observational findings as proof that semaglutide causes blindness or discontinue medication without consulting their physician.

    What changed

    • Claim: no-causation-established: unverified supported
  2. New evidence

    Large observational study reports elevated NAION incidence among semaglutide users

    Researchers published a retrospective matched-cohort analysis reporting higher observed rates of NAION among patients prescribed semaglutide. The study received widespread attention because it suggested a possible safety signal, while its authors emphasized that observational data cannot establish causality.

    What changed

    • Story status: breaking developing

Suggest a source

Point us to a primary source or a publisher correction. Every suggestion is reviewed by a human before anything changes — this is not voting on what’s true.

Confidence last reviewed July 1, 2026. Updates are append-only; nothing here is edited silently.